Category Archives: Company News

Fairbanks is Semifinalist for MilliporeSigma’s Start-Up Program at LabCentral

Fairbanks Pharmaceuticals Inc was selected as a semi-finalist in the competition for MilliporeSigma’s Start-Up program at LabCentral in Cambridge MA. The winner will be awarded a “Golden Ticket” of 1 year of space at one of the country’s leading and highly desirable biotechnology incubators, a fantastic opportunity to move to an environment that fosters partnerships and collaborations that can accelerate our therapeutic development activities.

On August 1, Dr. Alan Schneyer, Fairbanks Co-Founder and CEO, presented Fairbanks’ plans and progress to a highly selective board of judges composed of MilliporeSigma scientists and Lab Central Senior Managers. Results of the judges decision will be announced in mid-August.

Fairbanks Presents at MassCONNECT Final Showcase

Fairbanks Pharmaceuticals presented its unique and innovative approach to attacking the underlying pathology of diabetes by increasing insulin production from existing beta cells and simultaneously inducing regeneration of beta cells at the MassCONNECT Final Showcase on May 18th 2017.  The presentation was met with widespread interest from both pharma and private investors. 

The Final Showcase was the culmination of an eight-week mentorship program with a team of biotech and pharmaceutical industry leaders to help with strategic planning, identifying potential partners and financing, and developing a slide deck. 

MassBio Council MassConnect Program

Fairbanks CEO Alan Schneyer presenting at MassConnect
Fairbanks CEO Alan Schneyer presenting

Alan Schneyer and Elissa Brown gave Fairbanks’ introductory pitch today to MassBio’s 2017 Cycle 1 MassConnect mentors. Fairbanks was one of four biotech startups selected by MassBio to join the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation.

The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital.
MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks.

Click here for more information  on today’s kick-off.

Alan Schneyer (6th from right) and Elissa Brown (3rd from right) with other MassConnect participants

Boehringer-Ingelheim Boston Innovation Prize

(December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks from 30 applicants to compete for their Boston Innovation Prize. BI runs this competition to help sustain innovative pipelines for new breakthrough therapies by providing a Golden Ticket for Lab Central space (valued at $75,000) in Cambridge, MA. The panel of judges includes senior and founding members of Lab Central and BI’s venture capital fund, as well as other seed stage investor groups.

Fairbanks Pharmaceuticals to compete in semifinals of Diabetes Innovation Challenge

Fairbanks Pharmaceuticals has been selected as a semi-finalist in the Diabetes Innovation Challenge sponsored by the T1D Exchange, the Massachusetts Medical Device Development Center (M2D2) at UMass, the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).

The Challenge is a proposal- and presentation-based competition for small companies in the T1 and T2 space that are making real progress towards better outcomes for those diagnosed.  It offers the chance to win in-kind awards and receive early and later-stage validation of their ideas and products specific to Type 1 and Type 2 diabetes.

Read more about the Challenge, or come see  us at UMass Lowell on October 5th, 2016 at the pre-clinical “pitch-off.”

 

Fairbanks Pharmaceuticals awarded a Phase 1 SBIR grant for $192,101 by NIDDK/NIH

Dr. Alan Schneyer, CEO/CSO and Co-founder of Fairbanks Pharmaceuticals, is the Principal Investigator (PI) of an SBIR grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH). The award begins immediately and funds our research that will identify a number of candidate compounds using our proprietary screening bioassay, comparing them for biochemical and biological properties, and testing the top candidates for biological activity in islet culture assays.

The award lasts for a one year period. It is anticipated that the successful completion of this Phase 1 award will lead to a larger Phase 2 award, which will allow testing the biological activity of lead compounds in animals. The goal of Fairbanks Pharmaceuticals, and this SBIR grant, is to develop compounds that lead to regeneration of insulin-producing beta cells to replace those lost to either type 1 or type 2 diabetes and thereby partially or completely eliminate diabetes in these patients. Stay tuned for progress reports….